Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Diffuse Large B-cell Lymphoma: early-phase trial registry
3 of 6 indexed Relapsed Diffuse Large B-cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Relapsed Diffuse Large B-cell Lymphoma: 6 US clinical trials tracked, 3 recruiting.
Relapsed Diffuse Large B-cell Lymphoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is ADC Therapeutics S.A., running 1 of these trials.
Enrollment posture brief
Registry condition relapsed-diffuse-large-b-cell-lymphoma
OPEN 3 | RECR 50% | LATE 1 | EARLY 5 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Relapsed Diffuse Large B-cell Lymphoma lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Diffuse Large B-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Diffuse Large B-cell Lymphoma is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Relapsed Diffuse Large B-cell Lymphoma research.
ADC Therapeutics S.A. accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Relapsed Diffuse Large B-cell Lymphoma enrolment sits around 248 participants.
Median target enrolment is 248 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Relapsed Diffuse Large B-cell Lymphoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine
NCT04792489
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT04920617
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Abramson Cancer Center at Penn Medicine
NCT06458439
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
NCT04384484
Copanlisib Plus Venetoclax in R/R DLBCL
Dana-Farber Cancer Institute
NCT04572763
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT02348216
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Diffuse Large B-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Diffuse Large B-cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Diffuse Large B-cell Lymphoma page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Relapsed Diffuse Large B-cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ADC Therapeutics S.A. sponsors the most Relapsed Diffuse Large B-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See ADC Therapeutics S.A.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Diffuse Large B-cell Lymphoma condition card totals 6 registered trials; most-linked intervention Fludarabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.